DERIVATIVE OF INSULIN OR ITS PHYSIOLOGICALLY ACCEPTABLE SALT, PRECURSOR OF INSULIN DERIVATIVE, DNA SEQUENCE ENCODING PRECURSOR, EXPRESSION VECTOR COMPRISING MENTIONED DNA SEQUENCE, SUBSTRATE TRANSFORMED WITH MENTIONED EXPRESSION VECTOR, PHARMACEUTICAL COMPOSITION WITH REDUCING AND REGULATING BLOOD GLUCOSE LEVEL EFFECTIVENESS, RESPECTIVELY

FIELD: medicine, endocrinology, molecular biology, genetic engineering, medicinal industry. SUBSTANCE: invention relates to derivative of insulin or its physiologically acceptable salt with accelerated onset effect as compared with human insulin. In this insulin derivative asparagines (Asn) in position B3 of chain B is replaced for natural basic amino acid residue, and at least one amino acid residue in positions B27, B28 or B29 of chain B is replaced for another natural neutral or acid amino acid residue being asparagines (Asn) in position A21 of chain A can be replaced for Asp, Gly, Ser, Thr or Ala and phenylalanine (Phe) in position B1 of chain B and amino acid residue in position B30 of chain B can absent. Invention describes also DNA sequences encoding precursor of insulin derivative, expression vector comprising this DNA and also strains expressing insulin precursor and pharmaceutical composition with reducing and regulating blood glucose level effectiveness, respectively. The advantage of invention involves the development of preparation with accelerated onset of effect. EFFECT: valuable properties of composition. 23 cl, 6 tbl, 1 dwg, 8 ex